Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A pilot study of 15 subjects will be conducted to confirm an acute effect of grape seed extract on endothelial function. We then will perform a a randomized, double blind, placebo controlled crossover study designed to investigate the benefit of grape seed extract/vitamin C treatment on endothelial function. Participants (n=40) will take a food supplement containing 450 mg of grape seed extract and 1500 mg of vitamin C or matching placebo for four weeks and then cross over to the alternative treatment (active supplement or placebo) for four weeks. We will examine endothelial function before and after each of the two treatment periods. The study will provide information about the vascular effects of these compounds.
| Condition | Intervention |
|---|---|
|
Coronary Artery Disease |
Dietary Supplement: Grape seed extract and ascorbic acid |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Chronic Study of the Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function in Patients With Coronary Artery Disease |
- Brachial artery flow-mediated dilation [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Fingertip Pulse Amplitude Tonometry [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Carotid-femoral pulse wave velocity [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Serum markers of inflammation [ Time Frame: 1 month ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2007 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: Grape seed extract and ascorbic acid
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Coronary artery disease
Exclusion Criteria:
- Pregnancy
- Clinical history of other major illness including end-stage cancer, renal failure, hepatic failure, gastrointestinal disorders that may impair absorption, or other conditions that in the opinion of the principal investigator make a clinical study inappropriate.
- Treatment with an investigational new drug within the last 30 days.
- History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Vitamin E, Vitamin C, and beta carotene, lipoic acid, and other food or herbal supplements within 1 month of enrollment.
Contacts and Locations| United States, Massachusetts | |
| Boston Medical Center | |
| Boston, Massachusetts, United States, 02118 | |
| Principal Investigator: | Joseph A Vita, MD | Boston Medical Center |
More Information
No publications provided
| Responsible Party: | Joseph A. Vita, MD, Boston University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00554242 History of Changes |
| Other Study ID Numbers: | H-26356 |
| Study First Received: | November 5, 2007 |
| Last Updated: | June 16, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Boston University:
|
endothelium antioxidants flavonoids |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Ascorbic Acid Grape Seed Extract Antioxidants |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Vitamins Micronutrients Growth Substances Antineoplastic Agents, Phytogenic Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013